Camurus (CAMX) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Oczyesa to treat patients with acromegaly, a disease stemming from the pituitary gland.
CHMP's positive opinion is backed by seven clinical trials of the potential drug, which showcased a "higher proportion" of patients who responded to treatment with somatostatin analogues, achieving normalized insulin growth-factor-1 levels versus placebo groups, the company said.
One of the studies also showed improvement in symptoms and quality of life, according to a statement.
The company said a final decision on the market authorization is expected from the European Commission mid-year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。